Leaders in Pharmaceutical Business Intelligence (LPBI) Group

12:45 pm – 1:30 pm  3/27/2015  LIVE Keynote: Andrew Lo, Director of the MIT Laboratory for Financial Engineering  @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Reporter: Aviva Lev-Ari, PhD, RN

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

MassBio — the World Leader continues to focus on Patients

Mission Statement Signed Yesterday: 3/26/202015:

To advance MA Leadership in Life Science, add value to the industry and improve Patients Live

Keynote Speaker introduction by

Maurice Phelan, BioPrecess Leader, GE Healthcare Life Sciences

Keynote: Andrew Lo, Director of the MIT Laboratory for Financial Engineering

Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, the director of MIT’s Laboratory for Financial Engineering, and a principal investigator at MIT’s Computer Science and Artificial Intelligence Lab.  He received a B.A. in economics from Yale University in 1980, and an A.M. and Ph.D. in economics from Harvard University in 1984.

He has published extensively in academic journals (see http://web.mit.edu/alo/www/) and his most recent book is Hedge Funds: An Analytic Perspective.  His awards include Sloan and Guggenheim Fellowships, the Paul A. Samuelson Award, election to Academia Sinica, the American Academy of Arts and Sciences, the Econometric Society, and Time Magazine’s 2012 list of the “100 most influential people in the world.” He has also received teaching awards from the University of Pennsylvania and MIT.

His most recent research focuses on systemic risk, evolutionary models of investor behavior, and applying financial engineering to accelerate biomedical innovation.

LIVE PRESENTATION

•  Business of Science – Pharma vs Biotech 1994 to Present
• Index of Larger Pharma vs Biotech
• Pharma 200 on Pharma destroyed Sharholder value
• First Point of Inflection: Biotech since 2002 0 on 4/14/2002  – completion of the Human Genome Sequencing — A start point of accelerated growth
• Second Point of Inflection: Integrative analysis of human epigenome – MAPPING
• In 2006: 201 VC in Biotech in 2013 only 137 due to RISK
• $200 MM investmentm, 10yr horizon
• Probability of positive payoff is 5% (failure =95%)
• $6.9 Billion all investment in Biotech in 2014
• If we invest 150 Programs simultaneously?
• it will cost 30 Billion the Probability of 150 is 99.9% success
• Can MA Cure Cancer?
• A Megafund to eradicate Cancer – $30Billion
• Imagine a large reputable fund family for the Cure of Cancer
• who is willing to invest $3000 of your 401K
• with $30Billlion investment — we can Cure Cancer !!